Approval for the acs: 180 and the centaur afp assays on the advia centaur cp system.  The device, as modified, will be marketed under the trade name advia centaur cp afp and is indicated for in vitro diagnostic use in the quantitative determination of alpha-fetoprotein (afp) in 1) human serum and in amniotic fluid from specimens obtained at 15 and 20 weeks gestation, as an aid in detecting open neural tube defects (ntds) when used in conjunction with ultrasonography and amniography testing 2) human serum, as an aid in managing non-seminomatous testicular cancer when used in conjunction with physical examination, histology/pathology, and other clinical evaluation procedures, using the (bayer) system.